[Clinical and experimental study on gastrosia convalescens in treating chronic atrophic gastritis].
Gastrosia convalescens (GC) is a new drug for treating the Spleen-Yin Deficiency syndrome of chronic atrophic gastritis (CAG). Animal experiment has shown that GC has the function of promoting the regeneration of atrophic glands, and that of anti-inflammation, reinforcing, strengthening the stomach etc. It has the effect on the intestinal electric activity in dogs, mainly exciting in action, which was superior than that of domperidoni (P < 0.05). The result of clinical study has demonstrated that the marked effective rate of GC was 78.32%, CAG reversed into chronic superficial gastritis (CSG) in 30.0% of patients (60/200 cases), CAG into chronic superficial atrophic gastritis (CSAC) in 39.0% (78/200 cases) and CSAG into CSG in 39.02% (48/123 cases). The disappearance rate of metaplasia of intestinal epithelium and atypical hyperplasia were 39.1% and 38.14% respectively. There was a very significant difference in comparing with control group (P < 0.01).